병원내 감염 관리 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for hospital acquired infection control. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

• Hospital Acquired Infection Control Market Size (2024E): USD 7.13 Billion
• Projected Market Value (2033F): USD 10.1 Billion
• Global Market Growth Rate (CAGR 2024 to 2033): 3.9%

Hospital Acquired Infection Control Market - Report Scope:

Hospital acquired infections (HAIs) are infections that patients acquire while receiving treatment for medical or surgical conditions in healthcare settings. The market for HAI control includes products and services designed to prevent, diagnose, and treat infections such as urinary tract infections, surgical site infections, pneumonia, and bloodstream infections. Key products in this market include sterilization equipment, disinfectants, surveillance systems, and diagnostic devices. The HAI control market caters to hospitals, clinics, long-term care facilities, and diagnostic laboratories.

Market Growth Drivers:

The global hospital acquired infection control market is propelled by several key factors, including the rising prevalence of HAIs, increasing healthcare expenditures, and stringent regulations aimed at improving patient safety. Advances in sterilization and disinfection technologies, along with the development of innovative diagnostic tools, enhance the efficacy of infection control measures. Additionally, growing awareness and education about infection prevention among healthcare professionals and patients further drive market growth.

Market Restraints:

Despite promising growth prospects, the HAI control market faces challenges related to the high costs of advanced infection control products and equipment, regulatory compliance, and the need for continuous training of healthcare staff. The stringent regulations governing the manufacturing and use of infection control products impose compliance burdens on manufacturers and healthcare providers, affecting market entry barriers and operational costs. Furthermore, limited reimbursement coverage for certain infection control procedures poses challenges for market penetration, particularly in emerging economies with constrained healthcare budgets.

Market Opportunities:

The HAI control market presents significant growth opportunities driven by technological innovations, demographic trends, and evolving healthcare delivery models. The integration of digital health technologies, such as real-time infection surveillance systems and electronic health records, enhances the effectiveness of infection control programs. Additionally, the increasing adoption of minimally invasive surgical procedures and the expansion of outpatient care settings create new avenues for market players. Strategic partnerships, investment in research and development, and the introduction of cost-effective, user-friendly infection control solutions are essential to capitalize on emerging opportunities and sustain market leadership.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the hospital acquired infection control market globally?
• Which products and applications are driving adoption across different healthcare settings?
• How are technological advancements reshaping the competitive landscape of the HAI control market?
• Who are the key players contributing to the HAI control market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global HAI control market?

Competitive Intelligence and Business Strategy:

Leading players in the global hospital acquired infection control market, including 3M Company, Johnson & Johnson, and Becton, Dickinson and Company, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced infection control solutions, such as automated sterilization systems, advanced disinfectants, and rapid diagnostic tests, catering to diverse patient needs and clinical requirements. Collaborations with healthcare providers, medical device distributors, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the rapidly evolving infection control landscape.

Key Companies Profiled:

• Olympus Corporation
• Medivators Inc. (Cantel Medical Corp.)
• Getinge Group
• STERIS Plc.
• Belimed AG (Metall Zug)
• Steelco S.P.A
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd
• Merck & Co.
• Advanced Sterilization Products Services Inc. (Johnson & Johnson)
• Abbott Laboratories
• Bayer AG
• Alere Inc.
• The 3M Company
• Cepheid Inc
• UVision360 Inc.

Key Segments of the Hospital Acquired Infection Control Market

By Product :

• Heat Sterilization Equipment
• Low-Temperature Sterilization Equipment
• Radiation Sterilization Equipment
• Disinfection Equipment

By End User :

• Hospitals
• Ambulatory Surgical Centres
• Medical Institutions
• Diagnostic Laboratories
• Clinics

By Region :

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Key Success Factors

• 4.1. Product Adoption / Usage Analysis
• 4.2. Key Marketing & Promotion Strategies, By Manufacturers
• 4.3. Regulatory Landscape
• 4.4. Reimbursement Scenario.
• 4.5. Quality Monitoring Programs
• 4.6. PESTEL Analysis
• 4.7. Porter's Analysis.

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Industry Outlook
  • 5.1.3. Hospital Acquired Infection Market Overview
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Rising Focus on Personal Hygiene
  • 5.2.2. Increasing Prevalence of Infectious Diseases
  • 5.2.3. New Product Launch Activities
  • 5.2.4. Technological Advancements
  • 5.2.5. Increasing Minimally Invasive Procedures
  • 5.2.6. Susceptible Patients and Surgical Procedures
  • 5.2.7. Co-Existing Infections
  • 5.2.8. Increased Funding and Support from the Government
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. 2024 Market Scenario
• 6.2. COVID-19 and Impact Analysis
  • 6.2.1. By Product
  • 6.2.2. By End User
  • 6.2.3. By Region

7. Global Hospital Acquired Infection Control Market Demand (in Volume) Analysis 2019-2023 and Forecast, 2024-2033

• 7.1. Historical Market (Volume) Analysis, 2019-2023
• 7.2. Current and Future Market (Volume) Projections, 2024-2033
  • 7.2.1. Y-o-Y Growth Trend Analysis

8. Global Hospital Acquired Infection Control Market - Pricing Analysis

• 8.1. Regional Pricing Analysis, By Product
• 8.2. Pricing Break-up
  • 8.2.1. Manufacturer Level Pricing
  • 8.2.2. Distributor Level Pricing
• 8.3. Global Average Pricing Analysis Benchmark
• 8.4. Pricing Assumptions

9. Global Hospital Acquired Infection Control Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

• 9.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
• 9.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
  • 9.2.1. Y-o-Y Growth Trend Analysis
  • 9.2.2. Absolute $ Opportunity Analysis

10. Global Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033, By Product

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Product, 2019-2023
• 10.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Product, 2024-2033
  • 10.3.1. Heat Sterilization Equipment
    • 10.3.1.1. Moist Heat Sterilization Equipment
    • 10.3.1.2. Dry Heat Sterilization Equipment
  • 10.3.2. Low Temperature Sterilization Equipment
  • 10.3.3. Radiation Sterilization Equipment
  • 10.3.4. Disinfection Equipment
    • 10.3.4.1. Disinfector
      • 10.3.4.1.1. Washer Disinfector
      • 10.3.4.1.2. Flusher Disinfector
    • 10.3.4.2. Endoscopic Reprocessor Systems
      • 10.3.4.2.1. Single Basin Endoscopic Reprocessor Systems
      • 10.3.4.2.2. Dual Basin Endoscopic Reprocessor Systems
    • 10.3.4.3. Disinfectants
• 10.4. Market Attractiveness Analysis, By Product

11. Global Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033, By End User

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Bn) Analysis, By End User, 2019-2023
• 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, By End User, 2024-2033
  • 11.3.1. Hospitals
  • 11.3.2. Ambulatory Surgical Centers
  • 11.3.3. Medical Institutions
  • 11.3.4. Diagnostic Laboratories
  • 11.3.5. Clinics
• 11.4. Market Attractiveness Analysis, By End User

12. Global Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033, By Region

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Bn) and Volume (Units) Analysis by Region, 2019-2023
• 12.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2024-2033
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. South Asia
  • 12.3.5. East Asia
  • 12.3.6. Oceania
  • 12.3.7. Middle East and Africa
• 12.4. Market Attractiveness Analysis, By Region

13. North America Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Bn) and Volume (Units) Trend Analysis, By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2024-2033
  • 13.3.1. By Country
    • 13.3.1.1. U.S.
    • 13.3.1.2. Canada
  • 13.3.2. By Product
  • 13.3.3. By End User
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Product
  • 13.4.3. By End User
• 13.5. Key Market Participants - Intensity Mapping
• 13.6. Drivers and Restraints - Impact Analysis
• 13.7. Key Market Trends
• 13.8. Country-Level Analysis & Forecast
  • 13.8.1. U.S. Hospital Acquired Infection Control Market
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.1.2.1. By Product
      • 13.8.1.2.2. By End User
  • 13.8.2. Canada Hospital Acquired Infection Control Market
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.2.2.1. By Product
      • 13.8.2.2.2. By End User

14. Latin America Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Bn) and Volume (Units) Trend Analysis, By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2024-2033
  • 14.3.1. By Country
    • 14.3.1.1. Mexico
    • 14.3.1.2. Brazil
    • 14.3.1.3. Argentina
    • 14.3.1.4. Rest of Latin America
  • 14.3.2. By Product
  • 14.3.3. By End User
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Product
  • 14.4.3. By End User
• 14.5. Key Market Participants - Intensity Mapping
• 14.6. Drivers and Restraints - Impact Analysis
• 14.7. Key Market Trends
• 14.8. Country-Level Analysis & Forecast
  • 14.8.1. Mexico Hospital Acquired Infection Control Market
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Product
      • 14.8.1.2.2. By End User
  • 14.8.2. Brazil Surgical Imaging Market
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Product
      • 14.8.2.2.2. By End User
  • 14.8.3. Argentina Hospital Acquired Infection Control Market
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.3.2.1. By Product
      • 14.8.3.2.2. By End User

15. Europe Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Bn) and Volume (Units) Trend Analysis, By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2024-2033
  • 15.3.1. By Country
    • 15.3.1.1. U.K.
    • 15.3.1.2. Germany
    • 15.3.1.3. Italy
    • 15.3.1.4. France
    • 15.3.1.5. Spain
    • 15.3.1.6. Russia
    • 15.3.1.7. BENELUX
    • 15.3.1.8. Rest of Europe
  • 15.3.2. By Product
  • 15.3.3. By End User
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Product
  • 15.4.3. By End User
• 15.5. Key Market Participants - Intensity Mapping
• 15.6. Drivers and Restraints - Impact Analysis
• 15.7. Key Market Trends
• 15.8. Country-Level Analysis & Forecast
  • 15.8.1. U.K. Hospital Acquired Infection Control Market
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Product
      • 15.8.1.2.2. By End User
  • 15.8.2. Germany Hospital Acquired Infection Control Market
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Product
      • 15.8.2.2.2. By End User
  • 15.8.3. Italy Hospital Acquired Infection Control Market
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Product
      • 15.8.3.2.2. By End User
  • 15.8.4. France Hospital Acquired Infection Control Market
    • 15.8.4.1. Introduction
    • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.4.2.1. By Product
      • 15.8.4.2.2. By End User
  • 15.8.5. Spain Hospital Acquired Infection Control Market
    • 15.8.5.1. Introduction
    • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.5.2.1. By Product
      • 15.8.5.2.2. By End User
  • 15.8.6. Russia Hospital Acquired Infection Control Market
    • 15.8.6.1. Introduction
    • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.6.2.1. By Product
      • 15.8.6.2.2. By End User
  • 15.8.7. BENULUX Hospital Acquired Infection Control Market
    • 15.8.7.1. Introduction
    • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.7.2.1. By Product
      • 15.8.7.2.2. By End User

16. South Asia Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Bn) and Volume (Units) Trend Analysis, By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2024-2033
  • 16.3.1. By Country
    • 16.3.1.1. India
    • 16.3.1.2. Indonesia
    • 16.3.1.3. Malaysia
    • 16.3.1.4. Thailand
    • 16.3.1.5. Rest of South Asia
  • 16.3.2. By Product
  • 16.3.3. By End User
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Product
  • 16.4.3. By End User
• 16.5. Key Market Participants - Intensity Mapping
• 16.6. Drivers and Restraints - Impact Analysis
• 16.7. Key Market Trends
• 16.8. Country-Level Analysis & Forecast
  • 16.8.1. India Hospital Acquired Infection Control Market
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Product
      • 16.8.1.2.2. By End User
  • 16.8.2. Indonesia Hospital Acquired Infection Control Market
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Product
      • 16.8.2.2.2. By End User
  • 16.8.3. Malaysia Hospital Acquired Infection Control Market
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.3.2.1. By Product
      • 16.8.3.2.2. By End User
  • 16.8.4. Thailand Hospital Acquired Infection Control Market
    • 16.8.4.1. Introduction
    • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.4.2.1. By Product
      • 16.8.4.2.2. By End User

17. East Asia Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Bn) and Volume (Units) Trend Analysis, By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2024-2033
  • 17.3.1. By Country
    • 17.3.1.1. China
    • 17.3.1.2. Japan
    • 17.3.1.3. South Korea
  • 17.3.2. By Product
  • 17.3.3. By End User
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Product
  • 17.4.3. By End User
• 17.5. Key Market Participants - Intensity Mapping
• 17.6. Drivers and Restraints - Impact Analysis
• 17.7. Key Market Trends
• 17.8. Country-Level Analysis & Forecast
  • 17.8.1. China Hospital Acquired Infection Control Market
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Product
      • 17.8.1.2.2. By End User
  • 17.8.2. Japan Hospital Acquired Infection Control Market
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Product
      • 17.8.2.2.2. By End User
  • 17.8.3. South Korea Hospital Acquired Infection Control Market
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Product
      • 17.8.3.2.2. By End User

18. Oceania Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Bn) and Volume (Units) Trend Analysis, By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Market Taxonomy, 2024-2033
  • 18.3.1. By Country
    • 18.3.1.1. Australia
    • 18.3.1.2. New Zealand
  • 18.3.2. By Product
  • 18.3.3. By End User
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Product
  • 18.4.3. By End User
• 18.5. Key Market Participants - Intensity Mapping
• 18.6. Drivers and Restraints - Impact Analysis
• 18.7. Key Market Trends
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. Australia Hospital Acquired Infection Control Market
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.1.2.1. By Product
      • 18.8.1.2.2. By End User
  • 18.8.2. New Zealand Hospital Acquired Infection Control Market
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.2.2.1. By Product
      • 18.8.2.2.2. By End User

19. Middle East and Africa (MEA) Hospital Acquired Infection Control Market Analysis 2019-2023 and Forecast 2024-2033

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Bn) and Volume (Units) Trend Analysis, By Market Taxonomy, 2019-2023
• 19.3. Current and Future Market Size (US$ Bn) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2024-2033
  • 19.3.1. By Country
    • 19.3.1.1. GCC Countries
    • 19.3.1.2. Turkey
    • 19.3.1.3. South Africa
    • 19.3.1.4. North Africa
    • 19.3.1.5. Rest of Middle East and Africa
  • 19.3.2. By Product
  • 19.3.3. By End User
• 19.4. Market Attractiveness Analysis
  • 19.4.1. By Country
  • 19.4.2. By Product
  • 19.4.3. By End User
• 19.5. Key Market Participants - Intensity Mapping
• 19.6. Drivers and Restraints - Impact Analysis
• 19.7. Key Market Trends
• 19.8. Country Level Analysis & Forecast
  • 19.8.1. GCC Countries Hospital Acquired Infection Control Market
    • 19.8.1.1. Introduction
    • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.1.2.1. By Product
      • 19.8.1.2.2. By End User
  • 19.8.2. Turkey Hospital Acquired Infection Control Market
    • 19.8.2.1. Introduction
    • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.2.2.1. By Product
      • 19.8.2.2.2. By End User
  • 19.8.3. South Africa Hospital Acquired Infection Control Market
    • 19.8.3.1. Introduction
    • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.3.2.1. By Product
      • 19.8.3.2.2. By End User
  • 19.8.4. North Africa Hospital Acquired Infection Control Market
    • 19.8.4.1. Introduction
    • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.4.2.1. By Product
      • 19.8.4.2.2. By End User

20. Market Structure Analysis

• 20.1. Market Analysis by Tier of Companies
• 20.2. Market Share Analysis of Top Players
• 20.3. Market Presence Analysis
  • 20.3.1. Regional footprint of Players
  • 20.3.2. Product foot print by Players
  • 20.3.3. Channel Foot Print by Players

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Competition Benchmarking
• 21.3. Competition Deep Dive
  • 21.3.1. Olympus Corporation
    • 21.3.1.1. Company Overview
    • 21.3.1.2. Product Portfolio
    • 21.3.1.3. Sales Footprint
    • 21.3.1.4. Key Financials
    • 21.3.1.5. SWOT Analysis
    • 21.3.1.6. Key Developments
    • 21.3.1.7. Strategy Overview
      • 21.3.1.7.1. Marketing Strategy
      • 21.3.1.7.2. Product Strategy
      • 21.3.1.7.3. Channel Strategy
  • 21.3.2. Medivators Inc. (Cantel Medical Corp.)
    • 21.3.2.1. Company Overview
    • 21.3.2.2. Product Portfolio
    • 21.3.2.3. Sales Footprint
    • 21.3.2.4. Key Financials
    • 21.3.2.5. SWOT Analysis
    • 21.3.2.6. Key Developments
    • 21.3.2.7. Strategy Overview
      • 21.3.2.7.1. Marketing Strategy
      • 21.3.2.7.2. Product Strategy
      • 21.3.2.7.3. Channel Strategy
  • 21.3.3. Getinge Group
    • 21.3.3.1. Company Overview
    • 21.3.3.2. Product Portfolio
    • 21.3.3.3. Sales Footprint
    • 21.3.3.4. Key Financials
    • 21.3.3.5. SWOT Analysis
    • 21.3.3.6. Key Developments
    • 21.3.3.7. Strategy Overview
      • 21.3.3.7.1. Marketing Strategy
      • 21.3.3.7.2. Product Strategy
      • 21.3.3.7.3. Channel Strategy
  • 21.3.4. STERIS Plc.
    • 21.3.4.1. Company Overview
    • 21.3.4.2. Product Portfolio
    • 21.3.4.3. Sales Footprint
    • 21.3.4.4. Key Financials
    • 21.3.4.5. SWOT Analysis
    • 21.3.4.6. Key Developments
    • 21.3.4.7. Strategy Overview
      • 21.3.4.7.1. Marketing Strategy
      • 21.3.4.7.2. Product Strategy
      • 21.3.4.7.3. Channel Strategy
  • 21.3.5. Belimed AG (Metall Zug)
    • 21.3.5.1. Company Overview
    • 21.3.5.2. Product Portfolio
    • 21.3.5.3. Sales Footprint
    • 21.3.5.4. Key Financials
    • 21.3.5.5. SWOT Analysis
    • 21.3.5.6. Key Developments
    • 21.3.5.7. Strategy Overview
      • 21.3.5.7.1. Marketing Strategy
      • 21.3.5.7.2. Product Strategy
      • 21.3.5.7.3. Channel Strategy
  • 21.3.6. Steelco S.P.A
    • 21.3.6.1. Company Overview
    • 21.3.6.2. Product Portfolio
    • 21.3.6.3. Sales Footprint
    • 21.3.6.4. Key Financials
    • 21.3.6.5. SWOT Analysis
    • 21.3.6.6. Key Developments
    • 21.3.6.7. Strategy Overview
      • 21.3.6.7.1. Marketing Strategy
      • 21.3.6.7.2. Product Strategy
      • 21.3.6.7.3. Channel Strategy
  • 21.3.7. Pfizer Inc.
    • 21.3.7.1. Company Overview
    • 21.3.7.2. Product Portfolio
    • 21.3.7.3. Sales Footprint
    • 21.3.7.4. Key Financials
    • 21.3.7.5. SWOT Analysis
    • 21.3.7.6. Key Developments
    • 21.3.7.7. Strategy Overview
      • 21.3.7.7.1. Marketing Strategy
      • 21.3.7.7.2. Product Strategy
      • 21.3.7.7.3. Channel Strategy
  • 21.3.8. F. Hoffmann-La Roche Ltd
    • 21.3.8.1. Company Overview
    • 21.3.8.2. Product Portfolio
    • 21.3.8.3. Sales Footprint
    • 21.3.8.4. Key Financials
    • 21.3.8.5. SWOT Analysis
    • 21.3.8.6. Key Developments
    • 21.3.8.7. Strategy Overview
      • 21.3.8.7.1. Marketing Strategy
      • 21.3.8.7.2. Product Strategy
      • 21.3.8.7.3. Channel Strategy
  • 21.3.9. Merck & Co.
    • 21.3.9.1. Company Overview
    • 21.3.9.2. Product Portfolio
    • 21.3.9.3. Sales Footprint
    • 21.3.9.4. Key Financials
    • 21.3.9.5. SWOT Analysis
    • 21.3.9.6. Key Developments
    • 21.3.9.7. Strategy Overview
      • 21.3.9.7.1. Marketing Strategy
      • 21.3.9.7.2. Product Strategy
      • 21.3.9.7.3. Channel Strategy
  • 21.3.10. Advanced Sterilization Products Services Inc. (Johnson & Johnson)
    • 21.3.10.1. Company Overview
    • 21.3.10.2. Product Portfolio
    • 21.3.10.3. Sales Footprint
    • 21.3.10.4. Key Financials
    • 21.3.10.5. SWOT Analysis
    • 21.3.10.6. Key Developments
    • 21.3.10.7. Strategy Overview
      • 21.3.10.7.1. Marketing Strategy
      • 21.3.10.7.2. Product Strategy
      • 21.3.10.7.3. Channel Strategy
  • 21.3.11. Abbott Laboratories
    • 21.3.11.1. Company Overview
    • 21.3.11.2. Product Portfolio
    • 21.3.11.3. Sales Footprint
    • 21.3.11.4. Key Financials
    • 21.3.11.5. SWOT Analysis
    • 21.3.11.6. Key Developments
    • 21.3.11.7. Strategy Overview
      • 21.3.11.7.1. Marketing Strategy
      • 21.3.11.7.2. Product Strategy
      • 21.3.11.7.3. Channel Strategy
  • 21.3.12. Bayer AG
    • 21.3.12.1. Company Overview
    • 21.3.12.2. Product Portfolio
    • 21.3.12.3. Sales Footprint
    • 21.3.12.4. Key Financials
    • 21.3.12.5. SWOT Analysis
    • 21.3.12.6. Key Developments
    • 21.3.12.7. Strategy Overview
      • 21.3.12.7.1. Marketing Strategy
      • 21.3.12.7.2. Product Strategy
      • 21.3.12.7.3. Channel Strategy
  • 21.3.13. Alere Inc.
    • 21.3.13.1. Company Overview
    • 21.3.13.2. Product Portfolio
    • 21.3.13.3. Sales Footprint
    • 21.3.13.4. Key Financials
    • 21.3.13.5. SWOT Analysis
    • 21.3.13.6. Key Developments
    • 21.3.13.7. Strategy Overview
      • 21.3.13.7.1. Marketing Strategy
      • 21.3.13.7.2. Product Strategy
      • 21.3.13.7.3. Channel Strategy
  • 21.3.14. The 3M Company
    • 21.3.14.1. Company Overview
    • 21.3.14.2. Product Portfolio
    • 21.3.14.3. Sales Footprint
    • 21.3.14.4. Key Financials
    • 21.3.14.5. SWOT Analysis
    • 21.3.14.6. Key Developments
    • 21.3.14.7. Strategy Overview
      • 21.3.14.7.1. Marketing Strategy
      • 21.3.14.7.2. Product Strategy
      • 21.3.14.7.3. Channel Strategy
  • 21.3.15. Cepheid Inc.
    • 21.3.15.1. Company Overview
    • 21.3.15.2. Product Portfolio
    • 21.3.15.3. Sales Footprint
    • 21.3.15.4. Key Financials
    • 21.3.15.5. SWOT Analysis
    • 21.3.15.6. Key Developments
    • 21.3.15.7. Strategy Overview
      • 21.3.15.7.1. Marketing Strategy
      • 21.3.15.7.2. Product Strategy
      • 21.3.15.7.3. Channel Strategy
  • 21.3.16. UVision360 Inc.
    • 21.3.16.1. Company Overview
    • 21.3.16.2. Product Portfolio
    • 21.3.16.3. Sales Footprint
    • 21.3.16.4. Key Financials
    • 21.3.16.5. SWOT Analysis
    • 21.3.16.6. Key Developments
    • 21.3.16.7. Strategy Overview
      • 21.3.16.7.1. Marketing Strategy
      • 21.3.16.7.2. Product Strategy
      • 21.3.16.7.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology